Sun Pharma stock tumbles 8.5 per cent at market closing: Should you buy? Check for Rs 420 magical figure

Sun Pharmaceuticals Industries witnessed another tough day in share market as its stock fell by Rs 36.30 on Friday. Sun Pharmaceuticals closed at Rs 390.75, dipped 8.51 per cent to near six-year low. The stock hit by reports that a whistle-blower filed a complaint to regulators over transactions involving the top Indian drug-maker and its co-promoter. The whistle-blower alleged in a 172-page complaint that Sun Pharma`s distributor Aditya Medisales had performed transactions worth more than 58 billion rupees ($815 million) with Suraksha Realty, controlled by Sun`s co-promoter Sudhir Valia, a report by Moneylife magazine said. 

Sr. Equity Analyst, Rohit Singre, LKP Securities told Zee Business Online, ''The stock is down because of news, however technically it is weak right now. Investors are suggested to avoid until further clearance on the allegations.'' 

The stock has been in a correction mood since last month due to its corporate governance issues and a product recall. Shares of Sun Pharma, India`s top drug-maker lost nearly $1.5 billion of its market value on Friday. The complaint, done to the market regulator Securities and Exchange Board of India (SEBI), is the second in a period of month and comes as Sun Pharma is already struggling a product recall and regulatory investigation over reported insider trading.

TRENDING NOW

Anil Singhvi strategy December 1: Important levels to track in Nifty50, Nifty Bank today

RBI fines Bank of America, N.A., HDFC Bank

FIRST TRADE: Nifty hits record high, Sensex up 300 pts post-encouraging Q2 GDP print

Telangana Exit Poll 2023: Will BRS return to power for third consecutive term?

Instagram Threads now supports 'all languages' in search

Rajasthan Assembly Election Exit Polls Results 2023 LIVE: BJP holds edge in close fight with Congress in Rajasthan — Check BJP, Congress seat projection

Flair Writing IPO Listing LIVE updates: Strong listing expected today

Madhya Pradesh Election Exit Polls Results 2023 Live: Congress and BJP neck and neck in Madhya Pradesh; Check BJP, Congress seats

Share Market Today LIVE: Nifty scales all-time high of 20,222.8, Sensex trades nearly 300 pts higher

Chhattisgarh Exit Poll Results 2023 Live: Will Congress retain power in state? Here is what exit polls suggest

OPEC+ agrees to deepen voluntary oil output cuts

India vs Australia 4th T20I Free Live Streaming: When and Where to watch IND VS AUS T20I series Match LIVE on Mobile Apps, TV, Laptop, Online

Nifty 50 set to open at new record high, buoyed by strong growth data

HAL, Biocon, HPCL, Wipro: Stocks to watch out for on Friday

Dow rallies to year's highest close, caps blockbuster month

''The stock is weak on charts. No fresh buying is suggested until the stock crosses Rs 420. However once the stock stabilises, targets of Rs 480 to Rs 500 can be set,'' Singre added.

Watch this Zee Business tweet video:

#ZBizExclusive | 1 फरवरी से बदलने वाला है सब..जितने चैनल, उतना ही पैसा। TV देखना महंगा होगा या सस्ता? जानने के लिए देखिए @TRAI चेयरमैन आरएस शर्मा के साथ समीर दीक्षित की खास बातचीत।

पूरा इंटरव्यू देखें : https://t.co/j0JoA0O2pY @rssharma3 @sameerdixit16 @AnilSinghviZEE pic.twitter.com/oGVPLmckQJ

— Zee Business (@ZeeBusiness) January 18, 2019

However, The company mentioned in a filing to Indian stock exchange on Friday that it has not received the complaint.

In December, a media report said SEBI, helped by a whistle-blower tip off, was likely to reopen an insider trading case against Sun and probe alleged lapses by some of Sun`s promoters in raising funds overseas.

Earlier this month, Sun recalled muscle relaxant vecuronium bromide for injection due to the presence of glass.